Skip to main content

Table 3 Adverse events and laboratory abnormalities during the treatment period

From: Glecaprevir and pibrentasvir combination therapy for hepatitis C virus-infected Japanese patients on hemodialysis

 

Chronic hepatitis (n = 14) (%)

Compensated cirrhosis (n = 4) (%)

 

< Grade 3

≥ Grade 3

< Grade 3

≥ Grade 3

Pruritus

4 (28.6)

0

3 (75.0)

0

Headache

1 (7.1)

0

0

0

Bloating

0

0

1 (25.0)

0

Fatigue

0

0

1 (25.0)

0

Cellulitis

0

0

0

1 (25.0)